A great way to understand a company’s financial strength is by looking at its cash-to-debt ratio and interest coverage. Zimmer Biomet Holdings has a cash-to-debt ratio of 0.05, ranking worse than 95.6% of 841 companies in the Medical Devices & Instruments industry. Its overall financial strength is 6 out of 10, indicating fair financial health. Zimmer Biomet updated its FY 2023 earnings guidance on Wednesday, September, 20th. The company provided earnings per share (EPS) guidance of $7.47-$7.57 for the period, compared to the consensus EPS estimate of $7.50.

Zimmer Biomet Holdings has been profitable 8 times over the past 10 years. Over the past twelve months, the company had a revenue of $7.20 billion and Earnings Per Share (EPS) of $2.41. Its operating margin is 18.69%, ranking better than 82.3% of 836 companies in the Medical Devices & Instruments industry. Overall, Zimmer Biomet Holdings’ profitability Stop out is ranked 7 out of 10, indicating fair profitability. The GF Value is a proprietary measure that represents the current intrinsic value of a stock. It is calculated based on historical trading multiples, a GuruFocus adjustment factor derived from the company’s past performance and growth, and future business performance estimates.

These returns cover a period from January 1, 1988 through September 4, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

The “Halftime Report” traders give their top picks to watch for the second half.

Stocks to Focus On as Demand for Obesity Drugs Booms

The issuers of these securities may be an affiliate of Public, and Public (or an affiliate) may earn fees when you purchase or sell Alternative Assets. For more information on risks and conflicts of interest, defensive stocks definition see these disclosures. No offer to buy securities can be accepted, and no part of the purchase price can be received, until an offering statement filed with the SEC has been qualified by the SEC.

• Securities products offered by Open to the Public Investing are not FDIC insured.
• Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
• DVA’s earnings surpassed estimates in three of the trailing four quarters and missed once, with an average surprise of 21.4%.
• The musculoskeletal healthcare company continues to try to turn things around, with limited success in the first quarter.
• During the past 12 months, Zimmer Biomet Holdings’ ROIC was 5.05 while its WACC came in at 7.57.

However, a difficult macroeconomic situation leading to mounting expenses puts pressure on the operating margin. Comparing a company’s return on invested capital (ROIC) to its weighted average cost of capital (WACC) can also evaluate its profitability. ROIC measures how well a company generates cash flow relative to the capital it has invested in its business. WACC is the rate that a company is expected to pay on average to all its security holders to finance its assets.

Normally $25 each – click below to receive one report FREE:

The GF Value Line gives an overview of the ideal trading value of the stock. One of the most significant risks facing Zimmer Biomet is the potential for regulatory changes that could impact the industry. Changes in regulatory requirements could increase the costs and time required to bring new products to market, affecting Zimmer Biomet’s ability to innovate and compete.

ZBH Stock News Headlines

Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana. Alternative Assets.Brokerage services for alternative assets available on Public are offered by Dalmore Group, LLC (“Dalmore”), member of FINRA & SIPC. “Alternative assets,” as the term is used at Public, are equity securities that have been issued pursuant to Regulation A of the Securities Act of 1933 (as amended) (“Regulation A”). These investments are speculative, involve substantial risks (including illiquidity and loss of principal), and are not FDIC or SIPC insured. Alternative Assets purchased on the Public platform are not held in an Open to the Public Investing brokerage account and are self-custodied by the purchaser.

Our experts picked 7 Zacks Rank #1 Strong Buy stocks with the best chance to skyrocket within the next days. Integer Holdings has gained 28.5% compared with the industry’s 4.2% rise in the past year. When you see ZBH stock appear in the results, tap it to open up the purchase screen. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. New daily records for COVID-19 cases and hospitalizations mean these stocks are probably headed in opposite directions.

All regions benefited from continued recovery of elective procedures, backlog recapture and strong commercial execution and new product uptake. Before investing in a company, it’s crucial to assess its financial strength. Companies with poor financial strength pose a higher risk of permanent loss.

Premium Investing Services

Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Zimmer Biomet saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 2,170,000 shares, a decrease of 20.2% from the August 15th total of 2,720,000 shares.

StockGrader

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a best forex trading app trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.17% per year.

The company issued revenue guidance of $7.39 billion-$7.43 billion, compared to the consensus revenue estimate of $7.40 billion. Zimmer Biomet is expanding its product portfolio through innovation and acquisitions. The company has a robust pipeline of new products in development, including the Persona Revision Knee System and the ROSA Knee System. Zimmer Biomet is also pursuing strategic acquisitions to expand its presence in emerging markets and strengthen its position in existing markets. The company’s leadership team is led by President and CEO Bryan Hanson, who has been in his current role since 2017. Hanson has over 30 years of experience in the medical device industry and has held various executive positions in leading medical device companies.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. The Zacks Consensus Estimate for the company’s 2023 revenues is pegged at $7.40 billion. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer.